The US Food and Drug Administration's Model-Informed Drug Development Meeting Program: From Pilot to Pathway

被引：5
|
作者：
Madabushi, Rajanikanth [1 ]
Benjamin, Jessica [1 ]
Zhu, Hao [1 ]
Zineh, Issam [1 ]
机构：
[1] US FDA, Ctr Drug Evaluat & Res, Off Clin Pharmacol, Off Translat Sci, Silver Spring, MD 20993 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 116卷 / 02期
关键词：
D O I：
10.1002/cpt.3228
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：278 / 281
页数：4
相关论文
共 50 条
  • [21] Data standards for model-informed drug development: an ISoP initiative
    Andrijana Radivojevic
    Brian Corrigan
    Nicholas Downie
    Robert Fox
    Jill Fiedler-Kelly
    Huan Liu
    Murad Melhem
    David Radke
    Peter Schaefer
    Jing Su
    Maciej J. Swat
    Nathan S. Teuscher
    Neelima Thanneer
    Alice Zong
    Justin J. Wilkins
    Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45 : 659 - 661
  • [22] Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future
    Wu, Yue-E
    Zheng, Yuan-Yuan
    Li, Qiu-Yue
    Yao, Bu-Fan
    Cao, Jing
    Liu, Hui-Xin
    Hao, Guo-Xiang
    van den Anker, John
    Zheng, Yi
    Zhao, Wei
    ADVANCED DRUG DELIVERY REVIEWS, 2024, 211
  • [23] Model-Informed Drug Development: Steps Toward Harmonized Guidance
    Marshall, Scott
    Ahamadi, Malidi
    Chien, Jenny
    Iwata, Daisuke
    Farkas, Pavel
    Filipe, Augusto
    Frey, Nicolas
    Greene, Erin
    Kawai, Norisuke
    Li, Jian
    Lippert, Jorg
    Tshinanu, Flora Musuamba
    Manolis, Efthymios
    Peterson, Mark C.
    Sarem, Sarem
    Shebley, Mohamad
    Tegenge, Million
    Tsai, Chia-Hsun
    Tu, Chien-Lung
    Otsubo, Yasuto
    Wei, Jiawei
    Zhang, Lucia
    Zhu, Hao
    Karlsson, Kristin E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (05) : 954 - 959
  • [24] Methodology for the US food and drug administration's radionuclides in foods program
    Baratta, EJ
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 1998, 236 (1-2) : 139 - 144
  • [25] Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
    Liao, Michael Z.
    Lu, Dan
    Kagedal, Matts
    Miles, Dale
    Samineni, Divya
    Liu, Stephanie N.
    Li, Chunze
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1216 - 1230
  • [26] Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations
    van Wijk, Rob C.
    Alsoud, Rami Ayoun
    Lennernas, Hans
    Simonsson, Ulrika S. H.
    APPLIED SCIENCES-BASEL, 2020, 10 (07):
  • [27] Model-informed Drug Development (MIDD) Approach to Support Biopharmaceutical Development of Iberdomide
    Caroline Sychterz
    Ping Chen
    Ajay Saxena
    Hongxia Lin
    Lu Chen
    Yan Li
    Lu Gaohua
    Yiming Cheng
    The AAPS Journal, 27 (4)
  • [28] Accelerating Clinical Development of Janagliflozin, a Novel Antidiabetic Drug, Using Model-Informed Drug Development Strategy
    Liu, Dongyang
    Song, Ling
    Wang, Xiaoxu
    Liu, Xu
    Cao, Fangrui
    Liu, Hongzhong
    Ding, Yanhua
    Xiao, Xinhua
    Jiang, Ji
    Hu, Pei
    DIABETES, 2019, 68
  • [29] Model-Informed Drug Development Approaches to Assist New Drug Development in the COVID-19 Pandemic
    Xiong, Ye
    Fan, Jianghong
    Kitabi, Eliford
    Zhang, Xinyuan
    Bi, Youwei
    Grimstein, Manuela
    Yang, Yuching
    Earp, Justin C.
    Zheng, Nan
    Liu, Jiang
    Wang, Yaning
    Zhu, Hao
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 572 - 578
  • [30] Model-Informed Reverse and Forward Translation of Safety Risks in Drug Development
    Mettetal, Jerome T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (02) : 199 - 201
12345